A Drosophila model of mitochondrial disease phenotypic heterogeneity

Lucy Granat1, Debbra Y Knorr1, Daniel C Ranson1

  • 1Maurice Wohl Clinical Neuroscience Institute, King's College London, 5 Cutcombe Road, London SE5 9RX, UK.

Biology Open
|February 2, 2024
PubMed

Insights

Investigating complex I deficiency, this study used Drosophila to model disease heterogeneity. Different knockdown levels of ND-75 revealed distinct effects on behavior, metabolism, and gene expression, offering insights into mitochondrial disease variability.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Primary mitochondrial diseases stem from genetic mutations affecting mitochondrial function.
  • Complex I deficiency, caused by mutations in NDUFS1, presents with variable neurological symptoms and severity.
  • Phenotypic heterogeneity in mitochondrial diseases remains poorly understood.

Purpose of the Study:

  • To model the phenotypic heterogeneity of complex I deficiency using a Drosophila model.
  • To investigate the molecular and metabolic mechanisms underlying differential disease severity.

Main Methods:

  • Utilized RNAi targeting the Drosophila NDUFS1 homolog, ND-75, with varying efficiencies in neurons.
  • Assessed behavioral phenotypes, lifespan, mitochondrial morphology, ER-mitochondria contacts, and unfolded protein response (UPR).
  • Analyzed transcriptional responses and metabolic profiles, including neurotransmitter levels and specific metabolites.

Main Results:

  • Strong ND-75 knockdown caused severe phenotypes, altered mitochondrial and ER-mitochondria morphology, and UPR activation.
  • Weak ND-75 knockdown resulted in milder phenotypes with distinct transcriptional and metabolic alterations, affecting proteasome and immune genes.
  • Metabolic changes, including GABA levels, differed between strong and weak knockdown; 2-hydroxyglutarate (2-HG) was elevated only in strong knockdown.

Conclusions:

  • Drosophila ND-75 knockdown effectively models complex I deficiency heterogeneity.
  • Differential gene expression and metabolic shifts contribute to varying disease severity.
  • 2-HG emerges as a potential biomarker for severe neurological mitochondrial disease.